secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sunshine Biopharma Inc. (SBFM)
CIK:        0001402328
Form:       8-K
Filed at:   2024-02-15T23:59:59+00:00
Accession:  0001683168-24-001009
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sunshine Biopharma closes ~$10M underwritten public offering of units with warrants
--------------------------------------------------------------------------------

- 71,428,571 Units priced at $0.14/Common Unit and $0.139/Pre-Funded Unit; gross proceeds ~$10.0M.
- Each Unit includes common stock (or pre-funded warrant) plus 0.1 Series A ($2.10 strike) and 0.2 Series B ($2.38 strike) warrants.
- Underwriter Aegis Capital Corp. partially exercised over-allotment for 2,491,071 Series A and B warrants.
- Net proceeds earmarked for general corporate purposes and working capital.
- Offering closed on February 15, 2024; warrants expire in 30 months (Series A) and 60 months (Series B).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1402328/000168316824001009/0001683168-24-001009-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1402328/000168316824001009/sunshine_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-24-001009

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer